T-cell infiltration into tumors represents a critical bottleneck for immunemediated control of cancer. We previously showed that this bottleneck can be overcome by depleting immunosuppressive Foxpγ + regulatory T cells (Tregs), a process which can increase frequencies of tumor-infiltrating lymphocytes (TILs) through promoting development of specialized portals for lymphocyte entry, namely high endothelial venules (HEVs). In this paper, we used a carcinogen-induced tumor model, that allows for co-evolution of the tumor microenvironment and the immune response, to demonstrate that Treg depletion not only results in widespread disruption to HEV networks in lymph nodes (LNs) but activates CD8 + T cells, which then drive intratumoral HEV development. Formation of these vessels contrasts with ontogenic HEV development in LNs in that the process is dependent on TNF receptor and independent of lymphotoxin receptor-mediated signaling. These intratumoral HEVs do not express the chemokine CCLβ1, revealing a previously undescribed intratumoral blood vessel phenotype. We propose a model where Treg depletion enables a self-amplifying loop of T-cell activation, which promotes HEV development, T-cell infiltration, and ultimately, tumor destruction. The findings point to a need to test for HEV development as part of ongoing clinical studies in patients with cancer.
Introduction
Evidence indicates that the extent of T-cell infiltration into tumors is a key parameter influencing cancer immunity (1) (2) (3) (4) (5) . Our previous studies revealed an influence of Foxpγ + regulatory T cells (Treg) on the numbers of infiltrating T cells (6, 7) . Specifically, we found that Treg depletion promotes development of high endothelial venules (HEVs), whose presence is associated with significantly increased numbers of T cells and better control of tumor growth (6) . HEVs develop during ontogenic secondary lymphoid organ development, which is initiated by interactions between lymphotoxin (LT) receptor (LT R)-expressing lymphoid tissue organizer (LTo) cells and LTα 1 β -expressing lymphoid tissue inducer (LTi) cells (8) . A role for canonical LTi cells in intratumoral HEV neogenesis following Treg depletion was excluded in our previous study, indicating that this process is governed by different cues than those dictating HEV development in lymph nodes (LNs) (6) .
The current study set out to identify the mechanisms underpinning HEV development using a mouse model of carcinogen-induced fibrosarcoma that allows for evolving interactions between the immune system and cancer cells during the process of transformation. Such reciprocal interactions shape development of the tumor microenvironment, the nature of the immune response, and tumor immunogenicity (9) . A key feature of this carcinogen-induced tumor model is that vessels expressing peripheral node addressin (PNAd; the hallmark of HEV), are not detected in tumors from Treg-replete mice, indicating that Treg depletion is a prerequisite to development of HEV (6) . Therefore, the interactions of T and B lymphocytes and DCs, which become highly activated following Treg depletion (6, 10) , may be essential for coordinating HEV formation in the tumors described
Materials and Methods

Mice
We are grateful to Professor Rudensky for supplying Foxpγ DTR mice and to Professor Hammerling for supplying CD11c.DOG mice. Each have been described previously (10, 11) . Foxpγ DTR 
Tumor induction and diphtheria toxin administration
Anesthetized mice (8-15 weeks old) were injected subcutaneously with 400 μg of γ-methylcholanthrene (MCA; Sigma-Aldrich) in 100 μl olive oil to induce tumors as previously described (1β) . Mice were monitored for tumor development weekly for up to 18 months. Diphtheria toxin (DT; Sigma-Aldrich) in 100 μl P B S w a s administered by intraperitoneal (i.p.) injection (5ng/g body weight to deplete Tregs; 8ng/g body weight to deplete Tregs and CD11c + cells) every other day after palpable tumor development. Once tumors became palpable, they were measured using calipers every other day (tumor width, tumor height, tumor leg diameter and nontumor leg diameter), and tumor growth rate (k, days -1 ) was calculated using the difference between tumor and nontumor leg diameters by the following equation: Y= Y0 x exp (k x X). Mice were sacrificed before tumors reached 1.5cm in diameter or if tumors caused apparent discomfort (irritation or decreased mobility).
In vivo treatments
All treatments were administered by i.p. injection. Depleting CD4-and CD8specific antibodies were produced in-house (1γ) . Briefly, hybridomas expressing depleting CD4-and CD8-specific antibodies were produced in vitro and antibodies were purified on protein-G affinity columns. 100 μg anti-CD4 (clones YTS-191 and YTA-γ) and/or anti-CD8 (clones YTS-156 and YTS-169) mAbs were administered every other day beginning one day prior to DT. Mouse LT R.Fc (10 mg/kg body weight; received from Dr. Grogan or Prof. Ware (14) (15) (16) ) and Etanercept (5 mg/kg body weight; TNFRII.Ig; Enbrel ® , Amgen/Wyeth) were administered every other day alongside DT. β mg anti-mouse TNF mAb (MP6-XTββ; produced in-house as detailed above) was administered beginning one day before DT, after which 1 mg was given every other day. Anti-mouse LT-α mAb (clone S5Hγ), received from Dr Grogan (14) , was administered (6 mg/kg body weight) every other day beginning one day prior to DT. Mice received 100 μg of agonistic anti-LT R mAb (clone 4H8), received from Professor Ware (17, 18 ) every γ-4 days.
Dissection of tissues
Spleen and inguinal LNs were removed, and tumors were resected avoiding muscle, other tissues, and the popliteal LN.
Flow cytometry
Spleens and LNs were mashed through a 70 μm cell strainer (BD Biosciences) using the back of a syringe plunger. Tumors were mechanically dissociated by dicing into small (~1-βmm) pieces using a scalpel and then mashed through a 70 μm cell strainer using the back of a syringe plunger. Cell suspensions were resuspended in complete RPMI (cRPMI; RPMI [Invitrogen] plus β mM L-glutamine, 1 mM sodium pyruvate, pen/strep [50 μg/ml], and 10% FCS) and passed through a 70 μm cell strainer. Cells were washed with PBS, and red blood cells in tumor and spleen pellets were lysed using RBC lysis buffer (Biolegend). Cells were washed with PBS, stained using LIVE/DEAD Aqua (Invitrogen), then washed and Fc receptors blocked with anti-CD16/γβ (clone 9γ; eBioscience) before staining with surface antibodies (listed in Supplementary Table S1 ).
For intracellular TNF analysis, cells were stimulated in β4-well plates with β0 nM PMA (Sigma-Aldrich) and ionomycin (1 μg/ml; Sigma-Aldrich) at γ7°C for 4 hours. After 1 hour, GolgiStop (1μl/ml; BD Biosciences) was added. Cells were stained for surface markers and then TNF following fixation/permeabilization following the manufacturer's protocol (Foxpγ-staining kit; eBiosciences). Data were acquired on a FACS Canto II (BD Biosciences) and analyzed using FlowJo (TreeStar, USA). Paraffin-embedded tumors stained using anti-PNAd were scanned using a Zeiss Axio Scan.Z1 slide scanner. HEVs were indicated, including the vessel lumen, in Zen software to obtain vessel area calculated in μm β . Total HEV area was calculated as a proportion of the total tumor area. Sections were imaged using a Zeiss LSM710 or LSM800 confocal microscope, and serial images were assembled in Adobe Photoshop. Antibodies are listed in Supplementary Table S1 . T cells in stained, frozen tumors were counted per high power field of view, and an average of 10 fields of view was calculated per section.
Gene expression analysis
Data previously generated by MouseRef-8vβ.0 whole genome expression bead chip (Illumina) profiling were reanalyzed for statistically significant differences between Treg + , Treg -HEV lo and Treg -HEV hi groups (6) . Briefly, RNA was extracted from OCT embedded tissue using TRIzol reagent (Invitrogen). RNA integrity was assessed on the Agilent β100 Bioanalyzer, and samples with an RNA integrity number of 9 or more were used for gene expression profiling using MouseRef-8vβ.0 whole genome expression bead chip arrays and scanned on the iScan system (Illumina) as recommended by the manufacturer. Probe intensity values were corrected by background subtraction using Genome Studio software and subsequently log-β and baseline (median) transformed using Genespring software (Agilent) before analysis of genes. Heat maps were generated using GENE-E software (https://software.broadinstitute.org/GENE-E/index.html).
Statistical analyses
The statistical relationships (correlations) between sets of measured variables were tested using the non-parametric Spearman's correlation coefficient. The
statistical difference between group(s) was determined by the non-parametric Mann
Whitney t test or one-way ANOVA with Tukey's post test to compare pairs of means.
A P≤0.05 was considered significant. All statistical analyses were performed using GraphPad Prism software (GraphPad Prism Software, La Jolla, CA, USA). Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Results
Treg depletion disrupts LN HEV networks and induces intratumoral HEVs
We examined the impact of Treg depletion on LN architecture, focusing on HEV networks. Significant disruption was observed following loss of Tregs ( Fig. 1A 
and B). Demarcation between B-cell and T-cell zones was diminished, and T cells and
HEVs could be found throughout the swollen LN ( closer proximity on tumor HEVs. However, the flat endothelium that lines tumor HEVs is likely to hide subtle differences in cellular expression. Tumor HEVs also coexpressed the adhesion molecule MAdCAM-1 ( Supplementary Fig. S1 ). MAdCAM-1 is normally expressed by endothelial cells in all LN HEVs early in development, and then it is rapidly downregulated in peripheral LNs but not mucosal LNs where HEVs maintain MAdCAM-1 and PNAd expression (β4,β5). This observation indicates that tumor HEVs are newly formed vessels in the tumor microenvironment. In contrast to LN HEVs, tumor HEVs did not express CCLβ1. Instead, expression of this chemokine colocalized with lymphatic vessel endothelial hyaluronan receptor (LYVE)-1 expression in the tumor, suggesting restriction to lymphatic vasculature, which was the case for Treg-replete tumors ( Fig. 1K and L) . These findings indicate a phenotype which contrasts with previously described reports of intratumoral HEVs (β6-β8).
As described previously, HEV + tumors from Treg-depleted mice contain significantly increased numbers of CD8 + T cells and display significantly reduced growth rates relative to HEVtumors (6) . As shown in Fig. β , HEV area, calculated as a percentage of total tumor area following quantification of PNAd + vessels ( Fig. βA) , fitted a bifurcated pattern of distribution ( Fig. βB) . Using a threshold defined by median HEV area, we delineated tumors into HEV hi and HEV lo categories (Fig. βB) .
Because HEVs also co-expressed MAdCAM-1, HEV hi and HEV lo tumors also showed 'high' and 'low' MAdCAM-1 expression, respectively, for both quantity of MAdCAM-1 + vessels and intensity of MAdCAM-1 staining ( Supplementary Fig. S1 ). T lymphocytes are essential for intratumoral neogenesis of HEVs Given that Treg depletion results in a significant increase in number, proliferation, and activation of intratumoral T cells, particularly in HEV-containing tumors (6,10), we postulated that T cells influence intratumoral HEV neogenesis. To examine this, Treg-depleted tumor-bearing mice were injected with anti-CD4 and anti-CD8 (γγ-γ5). Treg-depleted mice treated simultaneously with anti-CD4 and anti-CD8 exhibited a significant reduction in tumor growth control (Fig. 4A ). Almost all tumors recovered from these mice contained no HEVs. Remaining vessels had weaker PNAd + staining ( Fig. 4B and C) , and a significant decrease in HEV area (Fig. 4F) relative to Treg-depleted tumors was seen. The most profound effect was observed upon CD8 + T cell-depletion ( Fig. 4B-F ). Considering T cell-depletion was suboptimal in Treg-depleted mice ( Supplementary Fig. Sβ) , these data show that a partial reduction in T-cell number, particularly CD8 + T cells, severely abrogates HEV neogenesis.
HEV neogenesis in tumors relies on TNFR but not LTβR signaling
To identify the molecular mechanisms underpinning HEV neogenesis in Tregdepleted tumors, we focused our attention on LT R and TNFR signaling pathways Treg-depleted mice with TNFRII.Ig decreased splenic FDCs and MAdCAM-1 expression, in-line with reports of wildtype animals ( Supplementary Fig. S4) (44, 45) .
Disruption of LN HEV morphology was observed in Treg-depleted mice receiving either LT R.Fc or TNFRII.Ig, with vessels appearing larger, often with more open lumen ( Supplementary Fig. S5 ). PNAd + HEV were readily detected in tumors of LT R.Fc-treated mice, and quantification revealed a significant increase in HEV area relative to Treg-depleted controls (Fig. 5A, B, and F) . In contrast, HEVs in tumors of mice receiving TNFRII.Ig were fewer in number (Fig. 5C) , and quantification revealed a profound reduction in total HEV area compared to controls ( Fig. 5F ). Administration of monoclonal antibodies specific for either of the two ligands for TNFRII, TNF and LTα, to tumor-bearing mice concurrently with Treg depletion also resulted in a decrease in HEV area relative to Treg-depleted controls ( Fig. 5D-F HEV lo controls (Fig. 5G ). When normalized for HEV area, these changes were more pronounced, suggesting a difference in HEV function following these treatments (Fig.   5H ). Although administration of an agonist LT R antibody to Treg-replete Foxpγ DTR mice induced PNAd + vessel formation in tumors, their presence was not accompanied by increased T-cell infiltration or reduced tumor growth relative to Treg + controls ( Supplementary Fig. S7 ). These data demonstrate that TNFR signaling is critical for development of functional HEV in tumors and indicate that blocking HEV development reduces the number of TILs and ability to control tumor growth.
HEV area and tumor growth correlate with TNF + tumor-infiltrating T cells
Given our data, it seems likely that cytokines produced by T cells drive HEV development via TNFR signaling. To address this, proportions of CD8 + T cells in tumors and lymphoid organs expressing intracellular TNF were correlated with HEV area in tumors. A significant positive correlation was found between the proportion of intratumoral (but not LN-derived or splenic) CD8 + T cells producing TNF and intratumoral HEV area (Fig. 6A) . These data directly index intratumoral HEV to TNF production by CD8 + TILs and support the premise that TNF-producing T cells are key drivers of HEV neogenesis in tumors. Additionally, proportion of TNF-producing CD8 + T cells also correlated with tumor growth rates (Fig. 6B ). Although we could not distinguish between LTα γ and surface-bound LTα using anti-LTα, we found that T cells isolated from Treg-depleted tumors express LTα in addition to TNF at the mRNA level ( Supplementary Fig. S8 ), consistent with the possibility that these TNFproducing T cells also produce LTα. Overall, the data are indicative of a pathway where Treg depletion leads to activation of T cells, which then produce TNF/LT γ. This, in turn, promotes blood vessel differentiation into HEVs, resulting in superior Tcell infiltration and tumor control ( Fig. 6C) .
Discussion
In the presence of Tregs, T cells entering carcinogen-induced tumors express multiple and overlapping inflammatory chemokine receptor pairs to guide their migration to tumors (46) . T cells also enter via aberrantly formed blood and lymphatic vessels (47) . It is thought that Tregs become enriched within the TIL pool through selective proliferation and retention within the tumor microenvironment (48) Models where tumors develop in vivo better represent the structural complexity of solid tumors with respect to the composition of the stroma, the myriad of cell-to-cell interactions occurring within, and tumor immunogenicity. Tumor cell lines already possess the mutational and epigenetic changes required to rapidly become palpable tumors, but injection of carcinogens can allow for evolving interactions between the immune system and cancer cells during the process of transformation. Sustained interactions between the immune system and tumor cells during this early phase leads to a gradual reduction in tumor immunogenicity (9) .
Effector lymphocyte-driven development of LN-like vasculature in tumors, which then promotes antitumor immunity, may only occur when antigen stimulation is sufficient to overcome local immunosuppression. Depleting Tregs can significantly reverse this immunosuppression, lowering the threshold for immune activation and enabling HEV development to occur in response to immune-edited tumors.
We observed that around 50% of tumors developed HEVs after Treg depletion. Depleting Tregs induced robust T-cell activation in all animals, indicating that although activation of these immune cell subsets is essential for HEV development, it is not sufficient to ensure that this occurs in all tumors. All tumors from Treg-replete mice contained some T cells. The range was small, and a similar proportion of these T cells produced TNF, indicating that the extent to which TNFproducing T cells infiltrate the tumor pre-DT treatment is not a determining factor in whether the tumors go on to develop HEVs post-treatment. (B) Correlation between tumor growth rate (k, days -1 ) and the proportion of CD8 + T cells expressing intracellular TNF in tumors. Statistical significance was determined by Spearman's correlation coefficient test (r statistic and P values are shown). n = 9. (C) Schematic summary of the mechanism presented herein.
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